Physician profile
Alan Smiy
NPI 1114965845
$1,575.09
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $132 · 2021: $982 · 2022: $318 · 2023: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.48 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $245.00 | 2020-2023 | Mounjaro |
| Abbvie INC. | $190.55 | 2021-2023 | Dalvance |
| Astrazeneca Pharmaceuticals LP | $101.58 | 2021-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.12 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $65.04 | 2022 | |
| Merck Sharp & Dohme LLC | $60.07 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.14 | 2022 | |
| Astellas Pharma US INC | $44.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.16 | 2020-2021 | |
| Pfizer INC. | $32.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.60 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.70 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.54 | 2021 | |
| Daiichi Sankyo INC. | $21.12 | 2020 | |
| Amarin Pharma, INC. | $20.75 | 2021 | |
| Genzyme Corporation | $19.28 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.99 | 2023 | |
| Nevro Corp. | $16.70 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $15.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Smiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.